Table 1.
Characteristics of 39 OCAC studies and 37 050 participants of European ancestry included in the Mendelian randomization analysis
| Type of study | Study acronyma,b,c | Country | Diagnosis (years) | Median (range) age at diagnosis | Invasive HGSC (N) | Invasive non-HGSC (N)d | Borderline cases (N) | Median (interquartile range) BMIe |
|---|---|---|---|---|---|---|---|---|
| Population-based | AUS | Australia | 2002-06 | 58 (19-80) | 508 | 224 | 1 | 25.9 (22.7-29.7) |
| DOV | USA | 2002-09 | 57 (35-74) | 510 | 255 | 327 | 25.1 (22.2-29.5) | |
| GER | Germany | 1993-98 | 57 (21-75) | 81 | 62 | 24 | − | |
| HAW | USA | 1993-2008 | 56 (27-87) | 36 | 22 | 20 | 24.4 (22.0-28.8) | |
| HOC | Finland | 1975-99 | 46 (18-86) | 106 | 76 | 8 | − | |
| HOP | USA | 2003-09 | 58 (25-94) | 338 | 167 | 71 | 27.4 (23.6-32.2) | |
| MAL | Denmark | 1994-99 | 57 (31-80) | 197 | 204 | 138 | 23.6 (21.5-26.1) | |
| MCC | Australia | 1990-2008 | 65 (45-79) | 31 | 23 | 0 | 26.6 (23.2-29.0) | |
| NCO | USA | 1999-2008 | 57 (20-75) | 373 | 255 | 171 | 26.1 (22.8-30.5) | |
| NEC | USA | 1992-2003 | 52 (21-78) | 367 | 243 | 232 | 24.7 (22.0-28.6) | |
| NJO | USA | 2002-09 | 60 (25-88) | 92 | 62 | 0 | 25.9 (22.3-30.4) | |
| NOR | Norway | 2001-10 | 51 (18-86) | 123 | 64 | 12 | − | |
| NTH | Netherlands | 1997-2008 | 55 (18-83) | 94 | 139 | 3 | 24.5 (22.2-27.0) | |
| OVA | Canada | 2002-09 | 58 (19-80) | 344 | 186 | 161 | − | |
| POL | Poland | 2000-04 | 56 (24-74) | 101 | 69 | 0 | 23.8 (22.0-26.4) | |
| SEA | UK | 1998-2011 | 57 (19-78) | 643 | 599 | 76 | − | |
| SOC | UK | 1993-98 | 62 (22-92) | 91 | 116 | 20 | − | |
| SRO | Scotland | 1999-2001 | 59 (34-84) | 89 | 31 | 0 | − | |
| STA | USA | 1997-2002 | 50 (20-64) | 141 | 81 | 10 | − | |
| TOR | Canada | 1995-2007 | 58 (26-85) | 339 | 205 | 0 | 25.7 (23.1-29.1) | |
| UCI | USA | 1993-2005 | 56 (18-86) | 154 | 102 | 141 | 24.9 (21.9-29.1) | |
| USC | USA | 1992-2010 | 57 (22-82) | 418 | 187 | 152 | 24.2 (21.7-28.1) | |
| Clinic-based | BAV | Germany | 2002-08 | 58 (24-83) | 42 | 41 | 5 | 25.4 (22.7-28.7) |
| BEL | Belgium | 2007-10 | 46 (19-87) | 188 | 74 | 0 | − | |
| HJO | Germany | 2007-11 | 54 (18-88) | 136 | 43 | 13 | − | |
| HMO | Belarus | 2006-11 | 45 (22-76) | 50 | 20 | 0 | − | |
| HSK | Germany | 2000-07 | 58 (18-81) | 103 | 21 | 9 | − | |
| LAX | USA | 1989-2008 | 58 (31-88) | 213 | 43 | 0 | − | |
| MAY | USA | 2000-2010 | 61 (20-93) | 516 | 154 | 79 | 26.1 (23.0-30.3) | |
| MDA | USA | 1997-2009 | 62 (23-88) | 190 | 59 | 0 | − | |
| MSK | USA | 1997-2010 | 57 (18-89) | 354 | 50 | 0 | − | |
| ORE | USA | 2007-11 | 58 (22-86) | 40 | 11 | 9 | − | |
| POC | Poland | 1998-2008 | 55 (23-82) | 200 | 81 | 0 | − | |
| PVD | Denmark | 2004-09 | 63 (30-88) | 121 | 39 | 0 | − | |
| RMH | UK | 1993-96 | 52 (26-73) | 49 | 60 | 7 | − | |
| UKO | UK | 2006-10 | 63 (19-89) | 329 | 277 | 0 | − | |
| WOC | Poland | 1997-2010 | 44 (20-81) | 131 | 45 | 2 | − | |
| Familial registry | GRR | USA | 1981-2012 | 48 (21-83) | 72 | 33 | 0 | − |
| UKR | UK | 1991-2009 | 54 (24-77) | 23 | 11 | 0 | − |
aSee Supplementary Table S1 for study names and references. BMI, body mass index; HGSC, high-grade serous ovarian cancer; OCAC, Ovarian Cancer Association Consortium.
bFor analysis, we combined case-only with case-control sites: HSK combined with GER; GRR with HOP; PVD with MAL; RMH, SOC, SRO, UKR with SEA and UKO; ORE with DOV; LAX with UCI.
cNineteen studies (AUS, BAV, DOV, GER, HAW, HOP, MAL, MAY, NEC, NJO, NTH, POL, PVD, SEA, STA, TOR, UCI, UKO, USC) were used in menopausal/hormonal replacement therapy analyses as they provided these data for > 50% of participants.
dHistological subtypes other than serous, mucinous, endometrioid and clear cell carcinoma are not included.
eRecent BMI (1-5 years before diagnosis). BMI is summarized for 16 studies where > 50% participants had data available. These 16 studies were also used in conventional BMI analyses, as they provided data on potential confounders (parity, use of oral contraceptives and hormone replacement therapy, and family history of ovarian or breast cancer) for > 50% of participants. BMI, body mass index; HGSC, high-grade serous ovarian cancer; OCAC, Ovarian Cancer Association.